Physician profile
Miles E Medrano
NPI 1366487514
$6,349.46
in general payments reported to CMS, 2019-2025
35 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $419 · 2021: $823 · 2022: $662 · 2023: $1,031 · 2024: $998 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,346 · Education: $44.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.22 |
| Education | $44.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,814.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $767.16 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $586.11 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $492.18 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $307.39 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $281.53 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $238.01 | 2019-2025 | Ocaliva |
| Braintree Laboratories, INC. | $204.98 | 2019-2024 | Sutab, Suflave |
| Qol Medical, LLC | $199.63 | 2019-2024 | Sucraid |
| Madrigal Pharmaceuticals | $175.82 | 2025 | Rezdiffra |
| Ardelyx, INC. | $151.26 | 2022-2025 | Ibsrela |
| Allergan, INC. | $127.46 | 2019 | |
| Ferring Pharmaceuticals INC. | $105.95 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $104.83 | 2023 | |
| Genzyme Corporation | $82.05 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $75.69 | 2024 | Voquezna |
| Celltrion USA INC. | $75.13 | 2024 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $67.01 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $58.18 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $50.13 | 2025 | Wegovy |
| Redhill Biopharma INC. | $46.51 | 2021 | |
| Fresenius Kabi USA, LLC | $38.63 | 2023 | Idacio |
| Ucb, INC. | $37.93 | 2019 | |
| Merck Sharp & Dohme LLC | $34.07 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $31.48 | 2025 | Zenpep |
| Exact Sciences Corporation | $30.08 | 2025 | The Cologuard Plus Collection Kit |
| Ironwood Pharmaceuticals, INC | $27.63 | 2020-2023 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.90 | 2023 | Cyltezo |
| Evoke Pharma, INC. | $20.44 | 2023 | Gimoti |
| Amgen INC. | $20.09 | 2023 | Avsola, Amjevita |
| Daiichi Sankyo INC. | $20.07 | 2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2024 | Iqirvo |
| Medtronic, INC. | $19.28 | 2023 | Interstim |
| Pfizer INC. | $17.69 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,608.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Medrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.